Pharma Mar, S.A. (PHM)
BME
Closed
Aug 25, 2026
Day's Range
82.5052 wk Range
64.00Overview - PHM - Pharma Mar, S.A.
Key Statistics
Valuation
Enterprise Value
1.32B
P/E (Trailing)
‪25.51‬
P/E (Forward)
‪13.12‬
PEG Ratio
‪13.12‬
Price / Sales (TTM)
‪6.50‬
Price / Book
‪5.67‬
EV / EBITDA
‪29.47‬
Profitability
Gross Margin
‪90.45%‬
Profit Margin
‪25.67%‬
Operating Margin
‪-2.83%‬
Return on Assets
‪6.54%‬
Return on Equity
‪24.81%‬
Ownership
Shares Outstanding
17.32M
Float
13.40M
Held by Insiders
‪27.21%‬
Held by Institutions
‪9.86%‬
Price stats
Beta
‪0.42‬
50-Day Avg
‪77.54‬
200-Day Avg
‪82.50‬
Dividends
Payout Ratio
‪0.00%‬
Frequency
Annual
Analyst Consensus
9 analysts
Average price target
‪€ 104.39‬Shariah Compliance
Report Date: Feb 20, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - PHM - Pharma Mar, S.A.
Peers - PHM - Pharma Mar, S.A.
Peer Comparison
Compared with companies in Biotechnology listed on BME.
- PHMBMEPharma Mar, S.A.1.44BMarket Cap+2.10%52-week change25.87P/E (Trailing)‪25.67%‬Profit Margin
- ATRYBMEAtrys Health, S.A.192.07MMarket Cap-13.83%52-week change—P/E (Trailing)‪-69.49%‬Profit Margin
- BSTBMEBiotechnology Assets S.A.16.35MMarket Cap-83.49%52-week change10.77P/E (Trailing)‪-55.83%‬Profit Margin
Profile Summary - PHM - Pharma Mar, S.A.
About
Pharma Mar, S.A. is a Spanish biopharmaceutical company headquartered in Colmenar Viejo, Madrid, specializing in the research, development, manufacturing, and commercialization of antitumor drugs derived from marine organisms. Founded in 1986 as a subsidiary of Zeltia, it pioneered the first entirely Spanish-developed…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
